ClinicalTrials.gg
Sign In

Neuroendocrine Tumors clinical trials

The registry lists 542 studies for Neuroendocrine Tumors across more than 10 countries. 135 are recruiting or about to start. 330 of them are mainly about Neuroendocrine Tumors (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 17 narrower conditions too, such as Melanoma: 4,781 studies, 943 open.

ClinicalTrials.gov finds 4,887 studies for Neuroendocrine Tumors. How that becomes 541 here

This page counts the studies the registry files under Neuroendocrine Tumors, and those it files under no condition that list Neuroendocrine Tumorsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 4,887Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4,021Filed under a narrower condition, counted on its own pageMelanoma 3,188 · Uveal Melanoma 156 · Pheochromocytoma 125 · Carcinoma, Medullary 117 · Neuroma, Acoustic 98 · Carcinoma, Neuroendocrine 93 · 9 more
  3. −106List Neuroendocrine Tumors as a condition, but the registry did not file them under itMost often written as “Pancreatic Neuroendocrine Tumor” (31), “Pancreatic Neuroendocrine Tumors” (12), and “Rectal Neuroendocrine Tumor” (5). The registry filed 41 of them under no condition at all, and the others under other conditions only, most often Adenoma, Islet Cell (41) and Pancreatic Neoplasms (17).
  4. −219Match it another way48 name it in the title, 2 in a keyword, and 169 by a synonym or other text the search reads.
  5. 541The count on this page

Get an email when these change. Save the Neuroendocrine Tumors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
219
Recruiting
112
Status unknown
60
Active, not recruiting
55
Terminated
48
Withdrawn
19

Phase

Phase 2
221
Phase 1
107
Phase 3
40
Early Phase 1
18
Phase 4
15

Where

United States
218
Italy
68
China
63
France
59
Spain
43
Canada
42

Who runs them

National Cancer Institute (NCI) (20) · Ipsen (17) · Novartis Pharmaceuticals (14) · Grupo Espanol de Tumores Neuroendocrinos (11) · University Medical Center Groningen (10) · Peking Union Medical College Hospital (10) · Memorial Sloan Kettering Cancer Center (9) · European Institute of Oncology (8)

What is being tested here

Drugs under test in Neuroendocrine Tumors studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Lutetium Lu 177 dotatate3423
Temozolomide3010
177Lu-octreotide, DOTA(0)-Tyr(3)-327
Olaparib304
Zanzalintinib313
Cabozantinib219
Surufatinib227
Capecitabine217
Fluorodeoxyglucose F18202
Somatostatin Receptor Agonist212

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 11 open · Immune checkpoint inhibitors 4 open · Antimetabolites 4 open · PARP inhibitors 4 open · Alkylating agents 3 open

Coming up

17phase 3 studies under way
64studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger. 12 (11%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 4 (4%) take healthy volunteers.

Recruiting studies that take each age, of 112
AgeWomenMen
109 (8%)8 (7%)
18109 (97%)108 (96%)
30110 (98%)109 (97%)
40109 (97%)108 (96%)
50109 (97%)108 (96%)
65107 (96%)106 (95%)
75103 (92%)102 (91%)
8587 (78%)86 (77%)

Across all 542 studies, recruiting or not: 8% stop at 75 or younger and 2% at 65; 11% take children; <1% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neuroendocrine Tumors studies take

Of 98 phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 154 mo37–75 · 54 studies——
Phase 1/284 mo52–122 · 29 studies——
Phase 265 mo42–88 · 98 studies—60 mo43–83 · 85 studies
Phase 351 mo39–85 · 25 studies——
Interventional, no phase56 mo43–102 · 35 studies——
Observational60 mo37–239 · 54 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting4

Results posted1

Newly registered3

Studies

Recruiting first, then most recently updated. Showing 50 of 542. Browse all 542 → or search them.